Ganymed Pharmaceuticals
Biopharmaceutical company that focuses on the development of therapeutic drugs for the treatment of solid cancers.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD1.9b (Public information from Oct 2016)
Company register number HRB 47318 (Mainz)
Mainz Rhineland-Palatinate (HQ & founding location)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | <1m | <1m | - | - |
| EBITDA | (10.9m) | 450m | 15.6m | (<1m) | - | - | - |
| % EBITDA margin | - | - | - | (78 %) | - | - | - |
| Profit | (35.8m) | (11.1m) | 371m | 10.7m | (<1m) | (<1m) | <1m |
| % profit margin | - | - | - | 1928 % | (78 %) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
CHF12.9m | Series A | ||
$14.4m | Series B | ||
€37.2m | Series C | ||
€65.0m | Late VC | ||
€45.0m | Series E | ||
$1.4b Valuation: $1.4b -84.5x EV/LTM EBITDA | Acquisition | ||
| Total Funding | CAD257m | ||
Related Content
Recent News about Ganymed Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.